BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12884094)

  • 21. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
    Tanaka T; Masuda H; Naito M; Tamai H
    Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apoptosis-inducing activity of cisplatin (CDDP) against human hepatoma and oral squamous cell carcinoma cell lines.
    Okamura M; Hashimoto K; Shimada J; Sakagami H
    Anticancer Res; 2004; 24(2B):655-61. PubMed ID: 15161008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evaluation of chemosensitivity test for cancer using the collagen gel embedded culture system--DNA ploidy pattern and chemosensitivity].
    Hara S; Fujii Y; Imanishi Y; Kurooka K; Nishiyama K; Yamada H; Wada T; Shindo K; Yasutomi M
    Gan To Kagaku Ryoho; 1993 Apr; 20(6):828-30. PubMed ID: 8489293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells.
    Takara K; Fujita M; Minegaki T; Yamamoto K; Takahashi M; Yokoyama T; Okumura K
    Eur J Pharm Sci; 2012 Feb; 45(3):272-81. PubMed ID: 22155546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines.
    Janss AJ; Levow C; Bernhard EJ; Muschel RJ; McKenna WG; Sutton L; Phillips PC
    Exp Cell Res; 1998 Aug; 243(1):29-38. PubMed ID: 9716446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mechanism for synergistic antitumor effect in the combination of 5-fluorouracil with cisplatin in vivo tumor models: from the view of biochemical modulation of 5-fluorouracil].
    Shirasaka T; Shimamoto Y; Ohshimo H; Kimura A; Fukushima M
    Gan To Kagaku Ryoho; 1991 Mar; 18(3):403-9. PubMed ID: 2003740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequence-dependence of cisplatin and 5-fluorouracil in advanced and recurrent gastric cancer.
    Koizumi W; Kurihara M; Hasegawa K; Chonan A; Kubo Y; Maekawa R; Iwasaki R; Sasai T; Fukuyama Y; Ishikawa K; Miyoshi K; Yasutake K; Hayakawa M
    Oncol Rep; 2004 Sep; 12(3):557-61. PubMed ID: 15289837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evaluation of chemosensitivity testing for patients with unresectable non-small cell lung cancer (NSCLC) using collagen gel droplet embedded culture drug sensitivity test (CD-DST).
    Kawamura M; Gika M; Abiko T; Inoue Y; Oyama T; Izumi Y; Kobayashi H; Kobayashi K
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):507-13. PubMed ID: 16896928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro chemosensitivity testing of human tumours by collagen gel droplet culture and image analysis.
    Tanigawa N; Kitaoka A; Yamakawa M; Tanisaka K; Kobayashi H
    Anticancer Res; 1996; 16(4A):1925-30. PubMed ID: 8712722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
    Wada H; Nagano H; Yamamoto H; Arai I; Ota H; Nakamura M; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Doki Y; Dono K; Nakamori S; Sakon M; Monden M
    Oncol Rep; 2007 Oct; 18(4):801-9. PubMed ID: 17786339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Fundamental study of combination chemotherapy with THP, 5-FU and CDDP for human KB carcinoma cell line and its multidrug resistant cell line KB-C1--usefulness of treatment with 5-FU preceding CDDP].
    Kishimoto H; Manno Y; Tanaka H; Moridera K; Urade M
    Gan To Kagaku Ryoho; 2001 Apr; 28(4):505-9. PubMed ID: 11329785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous infusion of 5-fluorouracil with versus without low-dose, consecutive administration of cisplatin in advanced colorectal cancer. A prospective randomized phase II study.
    Nakata B; Sowa M; Tsuji A; Kamano T; Sasaki K; Fukunaga Y; Takahashi M; Tsujitani S; Mikami Y; Mitachi Y; Nishimura S; Araki H; Yamamitsu S; Hirakawa K; Tominaga S; Shirasaka T; Inokuchi K
    J Exp Clin Cancer Res; 2007 Mar; 26(1):51-60. PubMed ID: 17550132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
    Nakamura M; Nagano H; Sakon M; Yamamoto T; Ota H; Wada H; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Dono K; Monden M
    J Hepatol; 2007 Jan; 46(1):77-88. PubMed ID: 17045692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weekly infusional high-dose 5-fluorouracil and leucovorin and biweekly cisplatin: a convenient treatment option in advanced gastric cancer.
    Kundel Y; Purim O; Figer A; Stemmer SM; Tichler T; Sulkes J; Sulkes A; Brenner B
    Med Sci Monit; 2008 Apr; 14(4):CR190-5. PubMed ID: 18376346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced induction of apoptosis in lung adenocarcinoma after preoperative chemotherapy with tegafur and uracil (UFT).
    Morio A; Miyamoto H; Izumi H; Futagawa T; Oh T; Yamazaki A; Konno H
    Surg Today; 2004; 34(10):822-7. PubMed ID: 15449150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines.
    Qin B; Tanaka R; Shibata Y; Arita S; Ariyama H; Kusaba H; Baba E; Harada M; Nakano S
    Anticancer Drugs; 2006 Apr; 17(4):445-53. PubMed ID: 16550003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
    Hasegawa Y; Goto M; Hanai N; Ijichi K; Adachi M; Terada A; Hyodo I; Ogawa T; Furukawa T
    Oral Oncol; 2007 Sep; 43(8):749-56. PubMed ID: 17112769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {alpha}-related apoptosis-inducing ligand/anticancer drug combinations.
    Meurette O; Lefeuvre-Orfila L; Rebillard A; Lagadic-Gossmann D; Dimanche-Boitrel MT
    Clin Cancer Res; 2005 Apr; 11(8):3075-83. PubMed ID: 15837763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
    Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
    Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways.
    Hwang JT; Ha J; Park OJ
    Biochem Biophys Res Commun; 2005 Jul; 332(2):433-40. PubMed ID: 15896711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.